Contribution of cervical cytology in the diagnostic work-up of patients with endometrial cancer

被引:16
作者
Amkreutz, L. C. M. [1 ,2 ]
Pijnenborg, J. M. A. [3 ]
Joosten, D. W. L. [1 ,2 ]
Mertens, H. J. M. M. [1 ,2 ]
Van Kuijk, S. M. J. [4 ]
Engelen, M. J. A. [1 ,2 ]
Bergmans, M. [5 ]
Nolting, W. E. [6 ]
Kruitwagen, R. F. P. M. [7 ,8 ]
机构
[1] Zuyderland Med Ctr, Dept Obstet & Gynecol, Sittard Geleen, Netherlands
[2] Zuyderland Med Ctr, Dept Obstet & Gynecol, Heerlen, Netherlands
[3] Radboud Univ Nijmegen, Dept Obstet & Gynecol, Med Ctr, Nijmegen, Netherlands
[4] Maastricht Univ, KEMTA Clin Epidemiol & Med Technol Assessment, Med Ctr, Limburg, Netherlands
[5] Sint Laurentius Hosp, Dept Obstet & Gynecol, Roermond, Netherlands
[6] SJG Weert, Dept Obstet & Gynecol, Weert, Netherlands
[7] Maastricht Univ, Dept Obstet & Gynecol, Med Ctr, Maastricht, Netherlands
[8] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands
关键词
cervical cytology; diagnosis; endometrial neoplasms; Papanicolaou smear; preoperative; LYMPH-NODE METASTASIS; GYNECOLOGIC-ONCOLOGY-GROUP; STAGE-I; SCORING SYSTEM; CARCINOMA; RISK; PREDICTION; PATHOLOGY; WOMEN; ADENOCARCINOMA;
D O I
10.1111/cyt.12511
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Introduction: Abnormal cervical cytology in patients with endometrial cancer (EC) has been associated with poor outcome. The aim of this study was to evaluate whether cervical cytology could contribute to an improved preoperative identification of high-grade EC (serous, clear cell, carcinosarcoma, high-grade endometrioid EC) in final histology. Methods: A retrospective cohort study was performed in five hospitals in the Netherlands. A total of 554 patients with EC that underwent primary surgical treatment between 2002 and 2010 were included. Primary outcome was defined as the contribution of abnormal cervical cytology in the preoperative identification of high-grade EC. As secondary outcome, recurrence-free survival (RFS) and disease-specific survival were determined based on preoperative cervical cytology, and compared to the currently established risk factors: myometrial invasion, high-grade and lymph vascular space invasion. Results: Abnormal cervical cytology was present in 45.1%. For patients with preoperative inconclusive and high-grade histology, the presence of abnormal cervical cytology contributed to an improved identification of high-grade EC in final histology (odds ratio [OR] 6.40 [95% confidence interval {CI}: 1.92-21.26]; OR 2.86 [95% CI: 1.14-7.14]), respectively. Patients with abnormal cervical cytology had a significant worse 5-year median RFS. Abnormal cervical cytology was independently related to RFS (hazard ratio 1.67 [95% CI: 1.04-2.68]) and disease-specific survival (hazard ratio 3.15 [95% CI: 1.74-5.71]). Conclusions: Abnormal cytology contributes to the preoperative identification of patients with high-grade EC, and is associated with compromised outcome. Future studies are warranted to determine whether cervical cytology could be incorporated into preoperative prediction models for lymph node metastasis.
引用
收藏
页码:63 / 70
页数:8
相关论文
共 38 条
[1]   The novel criteria for predicting pelvic lymph node metastasis in endometrioid adenocarcinoma of endometrium [J].
Akbayir, Ozgur ;
Corbacioglu, Aytul ;
Goksedef, B. Pinar Cilesiz ;
Numanoglu, Ceyhun ;
Akca, Aysu ;
Guraslan, Hakan ;
Bakir, Lale Vuslat ;
Cetin, Ahmet .
GYNECOLOGIC ONCOLOGY, 2012, 125 (02) :400-403
[2]   Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer [J].
AlHilli, M. M. ;
Podratz, K. C. ;
Dowdy, S. C. ;
Bakkum-Gamez, J. N. ;
Weaver, A. L. ;
McGree, M. E. ;
Keeney, G. L. ;
Cliby, W. A. ;
Mariani, A. .
GYNECOLOGIC ONCOLOGY, 2013, 131 (01) :103-108
[3]   Adjuvant therapy for patients with stage I papillary serous endometrial cancer [J].
Alobaid, A ;
Bruchim, I ;
Verkooijen, H ;
Gauthier, P ;
Petignat, P .
EJSO, 2006, 32 (03) :358-362
[4]   2 PATHOGENETIC TYPES OF ENDOMETRIAL CARCINOMA [J].
BOKHMAN, JV .
GYNECOLOGIC ONCOLOGY, 1983, 15 (01) :10-17
[5]   Management of women with uterine papillary serous cancer: A Society of Gynecologic Oncology (SGO) review [J].
Boruta, David M., II ;
Gehrig, Paola A. ;
Fader, Amanda Nickles ;
Olawaiye, Alexander B. .
GYNECOLOGIC ONCOLOGY, 2009, 115 (01) :142-153
[6]   Abnormal cervical cytology: a risk factor for endometrial cancer recurrence [J].
Brown, AK ;
Gillis, S ;
Deuel, C ;
Angel, C ;
Glantz, C ;
Dubeshter, B .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (03) :517-522
[7]  
Casparie M, 2007, CELL ONCOL, V29, P19
[8]   Diagnostic and therapeutic dilemma associated with atypical glandular cells on liquid-based cervical cytology [J].
Chummun, K. ;
Fitzpatrick, M. ;
Lenehan, P. ;
Boylan, P. ;
Mooney, E. ;
Flannelly, G. .
CYTOPATHOLOGY, 2012, 23 (06) :378-382
[9]   ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up [J].
Colombo, N. ;
Creutzberg, C. ;
Amant, F. ;
Bosse, T. ;
Gonzalez-Martin, A. ;
Ledermann, J. ;
Marth, C. ;
Nout, R. ;
Querleu, D. ;
Mirza, M. R. ;
Sessa, C. .
ANNALS OF ONCOLOGY, 2016, 27 (01) :16-41
[10]   Revised FIGO staging for carcinoma of the endometrium [J].
Creasman, William .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2009, 105 (02) :109-109